Cantor Fitzgerald started coverage on shares of Strongbridge Biopharma (NASDAQ:SBBP) in a report released on Tuesday morning. The brokerage issued a buy rating and a $14.00 price target on the biotechnology company’s stock.
“Right Team in Place. Following challenges faced by Taro Pharmaceuticals (TARO – NC) in commercializing KEVEYIS, we believe Strongbridge is well equipped to conduct a successful re-launch. The management team brings experience from an array of blue chip commercial pharmaceutical corporations: Shire (SHPG – OW, by Cantor Analyst Louise Chen), Bristol-Myers Squibb (BMY – NC), Johnson & Johnson(JNJ – NC), and Eli Lilly (LLY – NC). In addition to this critical know-how, Strongbridge has also hired an impressive sales force with experiences from orphan organizations such as Shire, Biomarin (BMRN – NC), and Retrophin (RTRX – NC).”,” the firm’s analyst wrote.
Several other research firms have also weighed in on SBBP. Zacks Investment Research lowered shares of Strongbridge Biopharma from a buy rating to a hold rating in a report on Wednesday, November 22nd. ValuEngine lowered shares of Strongbridge Biopharma from a hold rating to a sell rating in a report on Monday, October 2nd. HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. Finally, Oppenheimer started coverage on shares of Strongbridge Biopharma in a report on Thursday, August 10th. They set an outperform rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $12.25.
Several institutional investors have recently modified their holdings of the stock. Caxton Corp increased its holdings in shares of Strongbridge Biopharma by 2.2% in the third quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock valued at $38,053,000 after purchasing an additional 120,000 shares in the last quarter. Lyon Street Capital LLC acquired a new stake in shares of Strongbridge Biopharma in the third quarter valued at approximately $2,862,000. California State Teachers Retirement System acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $277,000. State Street Corp acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $443,000. Finally, Nexthera Capital LP acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at approximately $477,000. 57.53% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/12/06/strongbridge-biopharma-sbbp-receives-new-coverage-from-analysts-at-cantor-fitzgerald.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.